Come see the TKI selectivity comparison, the latest rivoceranib data, information on our pipeline, and more.
Learn how the mechanism of action of rivoceranib helps define its clinical potential.
See the relative selectivity of TKIs through our interactive touchscreen display.
Abstract Title: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer
Stop by booth 726a for a latte and explore the past, present, and future of treatment for unresectable hepatocellular carcinoma (uHCC).
Sign up to receive important information about rivoceranib, company news and updates, or to connect with a member of our team.